Cortagen

WHAT IT IS

Cortagen is a synthetic tetrapeptide, Ala-Glu-Asp-Pro, created by Vladimir Khavinson's research group in Saint Petersburg as part of a family of short peptide bioregulators intended to correspond to specific tissues, in this case the cerebral cortex.

It is presented in that research tradition as a synthetic counterpart to Cortexin, a polypeptide mixture extracted directly from animal brain cortex tissue, with the stated goal of achieving a similarly targeted effect from a single defined sequence rather than a variable extract.

Cortagen is not an approved medication anywhere and is not sold as a registered pharmaceutical product; it circulates mainly as a research chemical referenced in the Khavinson group's own publications.

FDA status: Cortagen has no FDA approval for any indication and has not been evaluated by the FDA.

WHAT RESEARCHERS ARE STUDYING IT FOR

The limited published literature, concentrated within the Khavinson research group and affiliated Russian institutions, has examined:

• Effects on aging markers and lifespan in animal models
• Proposed gene-regulatory activity in cortical or neural cell types
• General bioregulator theory, the idea that short peptides can exert tissue-specific signaling effects
• Comparisons with Cortexin as a synthetic alternative to a tissue extract

PROPOSED BIOLOGICAL MECHANISMS

The Khavinson bioregulator framework proposes that short peptides like Cortagen can bind DNA or chromatin regions and modulate gene expression in a tissue-selective manner, a mechanism the group has described across its broader peptide family.

This proposed mechanism has not been independently replicated to a degree that is widely accepted in mainstream molecular biology, and much of the supporting literature comes from the same research group and its affiliated publications.

AREAS OF RESEARCH INTEREST

• Whether Cortagen's proposed gene-regulatory activity can be independently confirmed outside the originating research group
• Whether any effects seen in animal models translate to human physiology at all
• Basic pharmacokinetic questions, including absorption and stability, that have not been clearly answered in published literature
• Why decades of bioregulator research have not progressed to registered human clinical trials outside Russia

WHAT THE EVIDENCE CURRENTLY SUGGESTS

Published research on Cortagen specifically is sparse and consists of animal and cell-based studies, almost entirely from the Khavinson group and closely affiliated researchers.

No registered human clinical trials evaluating Cortagen were identified in standard trial registries or peer-reviewed human trial literature.

Broader reviews of the Khavinson peptide bioregulator concept exist in the literature, but they largely summarize the same research lineage rather than offering independent outside confirmation.